Embracing anti-PD-1 immunotherapy in the treatment of esophageal cancer: Implications of positive phase III trials in advanced and resected esophageal cancer.

Hung-Yang Kuo Jhe-Cyuan Guo Chih-Hung Hsu

J Formos Med Assoc

Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address:

Published: January 2023

Download full-text PDF	Source
http://dx.doi.org/10.1016/j.jfma.2022.05.009	DOI Listing

Publication Analysis

Top Keywords

esophageal cancer

embracing anti-pd-1

anti-pd-1 immunotherapy

immunotherapy treatment

treatment esophageal

cancer implications

implications positive

positive phase

phase iii

iii trials

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!